Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 1.00 |
| ▸ | BCHE | P06276 | 10/20 | 0.65 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9106878 | 0.91 | ACHE (0.84) | ACHEBCHENOS1EPHX2CHRM1 | |
| SCHEMBL9584001 | 0.89 | ACHE (1.00) | ACHEBCHENOS1EPHX2 | |
| SCHEMBL9107496 | 0.83 | ACHE (0.71) | ACHEBCHENOS1EPHX2 | |
| SCHEMBL9104297 | 0.83 | ACHE (0.71) | ACHEBCHE | |
| SCHEMBL9106773 | 0.80 | ACHE (0.66) | ACHEBCHE | |
| SCHEMBL9105019 | 0.80 | ACHE (0.66) | ACHEBCHENOS1CHRM1 | |
| SCHEMBL9106523 | 0.79 | ACHE (1.00) | ACHEBCHECHRM1 | |
| Hydrochloric Acid SCHEMBL10656143 | 0.78 | ACHE (0.97) | ACHEBCHECHRM1 | |
| SCHEMBL9108831 | 0.76 | ACHE (0.60) | ACHEBCHE | |
| SCHEMBL9583069 | 0.75 | ACHE (0.67) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4897400-A | ENHANCING MEMORY | HOESCHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1990-01-30 | — | — | US | claimed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-5401749-A | Memory enhancers, cholinergic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-03-28 | — | — | US | disclosed |
| US-4897400-A | ENHANCING MEMORY | HOESCHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1990-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ACHE 1832/4885BCHE 3324/4885NOS1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.